Spots Global Cancer Trial Database for egfr mutations

Every month we try and update this database with for egfr mutations cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Study of Erlotinib in Combination With Bortezomib	NCT00895687	Advanced Cancer	Erlotinib Hydro... Bortezomib	-	M.D. Anderson Cancer Center
Study of Erlotinib in Combination With Bortezomib	NCT00895687	Advanced Cancer	Erlotinib Hydro... Bortezomib	-	M.D. Anderson Cancer Center
Study of Erlotinib in Combination With Dasatinib	NCT00895128	Advanced Cancer	Erlotinib Hydro... Dasatinib	18 Years -	M.D. Anderson Cancer Center
A Non-interventional Study (NIS) Registry for the Epidemiological and Scientific Evaluation of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) (Stage IIIB/IV Non-small Cell Lung Cancer).	NCT01153399	Non Small Cell ...		-	AstraZeneca
Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation	NCT01405079	Non-small Cell ...	Gefitinib Vinorelbine+Cis...	18 Years - 75 Years	Guangdong Association of Clinical Trials
Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone	NCT01513174	Non Small Cell ...	Gefitinib Gefitinib plus ...	18 Years -	Spanish Lung Cancer Group
A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study	NCT03042013	Subjects With N...	ASP8273	18 Years -	Astellas Pharma Inc
Mutations in the Epidermal Growth Factor Receptor(EGFR) Gene in Non-Small Cell Lung Carcinoma (NSCLC) and the Relation to Response of Treatment With Erlotinib	NCT00815971	Non-Small Cell ...		18 Years -	Aarhus University Hospital
Understanding Mechanisms of Acquired Resistance to BIBW2992	NCT01074177	Non-small Cell ... EGFR Mutations	BIBW 2992	18 Years -	Massachusetts General Hospital
A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study	NCT03042013	Subjects With N...	ASP8273	18 Years -	Astellas Pharma Inc
Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC	NCT05813522	Non Small Cell ...	Furmonertinib M...	18 Years -	First Affiliated Hospital of Zhejiang University
Study of EGFR-TKI to Asymptomatic Brain Metastases of NSCLC	NCT02250846	Asymptomatic Br...	EGFR-TKI	18 Years - 70 Years	Wuhan Union Hospital, China
Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW	NCT06355609	Non-small Cell ...	sunvozertinib i...	18 Years -	Hunan Province Tumor Hospital
An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations	NCT01646125	Advanced Non Sm...	AUY922 Docetaxel Pemetrexed	18 Years -	Novartis
Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC	NCT06348927	Non-Small Cell ...	sunvozertinib i...	18 Years -	Hunan Province Tumor Hospital
Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations	NCT01953926	Solid Tumors Ha...	Neratinib Fulvestrant Trastuzumab Paclitaxel	18 Years -	Puma Biotechnology, Inc.
An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations	NCT01646125	Advanced Non Sm...	AUY922 Docetaxel Pemetrexed	18 Years -	Novartis

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: